Umicore targets 30% market share in platinum APIs

Published: 19-Oct-2009
Ingredients

Umicore, a developer of metal based APIs for the pharmaceutical industry, has built a US$10m platinum based API plant in Buenos Aires, Argentina in an effort to improve quality and become a market leader in platinum APIs.


Umicore, a developer of metal based APIs for the pharmaceutical industry, has built a US$10m platinum based API plant in Buenos Aires, Argentina in an effort to improve quality and become a market leader in platinum APIs.

The GMP-approved plant became fully operational earlier this year and uses the company's precious metal chemistry expertise to produce platinum APIs for oncology products.

Umicore currently enjoys a 30% market share in Latin America with its Cis-Platin, Carbo-Platin and Oxali-Platin compounds.

"The capacity of the new plant allows us to supply 50% of the worldwide demand," says Matthias Grehl, Umicore's business line manager. "We target a 30% market share in platinum APIs by 2015."

Grehl says Umicore is also in talks with partners to develop "new, maybe gold-based" products at the Buenos Aires plant in the future.

  • Companies:
  • Umicore Group
See more

You may also like

Media

Brenntag North America announces collaboration with Umicore

Read more
The partnership will focus on the distribution of polyurethane and polyester catalysts

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Logical Biological expands its raw pharma material development and supply capabilities with new lab The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
  3. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  4. Shasun Chemicals and Drugs Limited
  5. Olon Spa Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Media

Brenntag North America announces collaboration with Umicore

The partnership will focus on the distribution of polyurethane and polyester catalysts
Ingredients

Umicore receives world first CEP-certificate for zinc oxide

EDQM grants Umicore the world’s first CEP-Certificate of Suitability for zinc oxide
Ingredients

Umicore’s Argentinian facility for anticancer APIs passes first European cGMP audit

Materials group has been making further improvements to the plant in Pilar, Buenos Aires
Ingredients

SiliCycle to distribute Umicore's precious metal-based catalysts in North America

<p>Canada-based SiliCycle, a fine chemistry company specialising in silica-based products, is to sell Belgium-based Umicore\'s precious metal-based homogenous catalysts to the North American life science industry.</p>
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Subscribe now